Drug-emergent metabolic syndrome in patients with schizophrenia receiving atypical (second-generation) antipsychotics

Indian Journal of Psychiatry

Volumn 53, Issue 2, 2011, Pages 128-133

  Gautam, Shiv ^a   Meena, Parth Singh ^b,c  

^a SMS MEDICAL COLLEGE   (India)

^b MG Medical College Jaipur   (India)

^c NONE   (India)

Author keywords

Atypical antipsychotics; Metabolic syndrome; Schizophrenia

Indexed keywords

CLOZAPINE; GLUCOSE; HALOPERIDOL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; OLANZAPINE; RISPERIDONE; TRIACYLGLYCEROL;

ADULT; ARTICLE; BLOOD PRESSURE; BLOOD PRESSURE MEASUREMENT; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; PROSPECTIVE STUDY; PSYCHOPHARMACOTHERAPY; SCHIZOPHRENIA; SIDE EFFECT; TREATMENT DURATION; TRIACYLGLYCEROL BLOOD LEVEL; WAIST CIRCUMFERENCE;

EID: 79960247981     PISSN: 00195545     EISSN: 19983794     Source Type: Journal    
DOI: 10.4103/0019-5545.82537     Document Type: Article

References (31)

1. Osby U, Correia N, Brandt L, Ekbom A, Sparén P. Mortality and causes of death in schizophrenia in Stockholm county, Sweden. Schizophr Res 2000;29:21-8.
2. Hennekens CH, Hennekens AR, Hollar D, Casey DE. Schizophrenia and increased risks of cardiovascular disease. Am Heart J 2005;150:1115-21. (Pubitemid 41773510)
3. Allebeck P. Schizophrenia: A life shortening disease. Schizophr Bull 1989;15:81-9
4. Black DW, Fisher R. Mortality in DSM-III-R schizophrenia. Schizophr Res 1992;7:109-16
5. Lambert TJ, Velakoulis D, Pantelis C. Medical comorbidity in schizophrenia. Med J Aust 2003;178:S67-70. (Pubitemid 36591938)
6. Casey DE. Metabolic issues and cardiovascular diseases in patients with psychiatric disorders. Am J Med 2005;118:15s-22.
7. Lakka HM, Laaksonen DE, Lakka TA, Niskanen LK, Kumpusalo E, Tuomilehto J, et al. The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA 2002;288:2709-16. (Pubitemid 35403784)
8. Lempiäinen P, Mykkänen L, Pyörälä K, Laakso M, Kuusisto J. Insulinresistance syndrome predicts coronary heart disease events in elderly nondiabetic men. Circulation 1999;100:123-8. (Pubitemid 29330009)
9. Kekäläinen P, Sarlund H, Pyörälä K, Laakso M. Hyperinsulinemia cluster predicts the development of Type 2 diabetes independent of a family history of diabetes. Diabetes Care 1999;22:86-92. (Pubitemid 29028303)
10. Isomaa B, Almgren P, Tuomi T, Forsen B, Lahti K, Nissen M, et al. Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care 2001;24:683-9. (Pubitemid 32893993)
11. Trevisan M, Liu J, Bahsas FB, Menotti A (Risk Factor and Life Expectancy Research Group): Syndrome X and mortality: A population-based study. Am J Epidemiol 1998;148:958-66.
12. Citrome L. Metabolic syndrome and cardiovascular disease. J psychopharma 2004;19:84-93. (Pubitemid 44567862)
13. Liese A, Mayer-Davis E, Haffner S. Development of the multiple metabolic syndrome: An epidemiologic perspective. Epidemiol Rev 1998;20:157-72. (Pubitemid 29045104)
14. Lieberman JA 3rd, Metabolic changes associated with antipsychotic use. Prim Care Companion J Clin Psychiatry 2004;6:8-13.
15. Brown S, Birtwistle J, Roe L, Thompson C. The unhealthy lifestyle of people with schizophrenia. Psychol Med 1999;29:697-701. (Pubitemid 29261358)
16. Ryan MC, Collins P, Thakore JH. Impaired fasting glucose tolerance in first-episode, drug-naive patients with schizophrenia. Am J Psychiatry 2003;160:284-9. (Pubitemid 41110453)
17. Holmberg SK, Kane C. Health and self-care practices of persons with schizophrenia. Psychiatr Serv 1999;50:827-9. (Pubitemid 29258962)
18. American Diabetic Association. Consensus development conference on antipsychotic drugs and obesity and diabetes. Diabetes Care 2004;27: 596-601.
19. Kane JM. Extrapyramidal side effects are unacceptable. Eur Neuropsychopharmacol 2001;11:S397-403.
20. Correll CU, Leucht S, Kane JM. Lower risk for tardive dyskinesia associated with second-generation antipsychotics: A systematic review of 1-year studies. Am J Psychiatry 2004;161:414-25. (Pubitemid 38326094)
21. Leucht S, Pitschel-Walz G, Abraham D, Kissling W. Efficacy and extrapyramidal side-effects of the new antipsychotics olanzapine, quetiapine, risperidone, and sertindole compared to conventional antipsychotics and placebo. A meta-analysis of randomized controlled trials. Schizophr Res 1999; 35:51-68. (Pubitemid 29023554)
22. Buckley PF. Broad therapeutic uses of atypical antipsychotic medications. Biol Psychiatry 2001;50:912-24. (Pubitemid 34020702)
23. Allison DB, Mentore JL, Heo M, Chandler LP, Cappelleri JC, Infante MC, et al. Antipsychotic-induced weight gain: A comprehensive research synthesis. Am J Psychiatry 1999;156:1686-96. (Pubitemid 29517559)
24. Masand PS. Relative weight gain among antipsychotics. J Clin Psychiatry 1999;60:706-8.
25. Wetterling T. Bodyweight gain with atypical antipsychotics: A comparative review. Drug Saf 2001;24:59-73. (Pubitemid 32113367)
26. Newcomer JW, Haupt DW, Fucetola R, Melson AK, Schweiger JA, Cooper BP, et al. Abnormalities in glucose regulation during antipsychotic treatment of schizophrenia. Arch Gen Psychiatry 2002;59:337-45. (Pubitemid 34275252)
27. Perez-Iglesias R, Crespo-Facorro B, Amado JA, Garcia-Unzueta MT, Ramirez-Bonilla ML, Gonzalez-Blanch C, et al. A 12-week randomized clinical trial to evaluate metabolic changes in drug-naive, first-episode psychosis patients treated with haloperidol, olanzapine, or risperidone. J Clin Psychiatry 2007;68:1733-40. (Pubitemid 350247503)
28. Saddichha S, Manjunatha N, Ameen S, Akhtar S. Effect of olanzapine, risperidone, and haloperidol treatment on weight and body mass index in first episode schizophrenia patients in India: A randomized, double-blind, controlled, prospective study. J Clin Psychiatry 2007;68:1793-8. (Pubitemid 350247510)
29. Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005;353:1209-23. (Pubitemid 41345943)
30. Bustillo JR, Buchanan RW, Irish D, Breier A. Differential effect of clozapine on weight: A controlled study. Am J Psychiatry 1996;153:817-9. (Pubitemid 26170545)
31. Lindenmayer JP, Czobor P, Volavka J, Citrome L, Sheitman B, McEvoy JP, et al. changes in glucose and cholesterol levels in patients with schizophrenia treated with typical or atypical antipsychotics. Am J Psychiatry 2003;160:290-6. (Pubitemid 41110454)